DOD Ovarian Cancer, Clinical Trial Academy – Early-Career Investigator Award
ID: 358736Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358736
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award for Fiscal Year 2025. This grant aims to support early-career investigators in conducting clinical trials focused on ovarian cancer, emphasizing professional development, intensive mentoring, and networking opportunities. The program is critical for enhancing the research landscape in ovarian cancer, with an estimated total funding of approximately $1.4 million available for a maximum of four years. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due on September 11, 2025, and can reach out to the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further information.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942525OCRPOCCTAECI_GG.pdf
    The Department of Defense's Ovarian Cancer Clinical Trial Academy (OCCTA) is offering the Early-Career Investigator Award for FY25, aimed at supporting emerging scientists in conducting clinical trials related to ovarian cancer. The program is designed to foster professional development, provide intensive mentoring, and facilitate networking among Early-Career Investigators (ECIs). Notably, applicants must be within 12 years of their last postdoctoral position and commit at least 25% of their time to the award activities. The grant, totaling approximately $1.4 million per award for a maximum of four years, requires a two-step application process, starting with a pre-application due on June 12, 2025, followed by a full application due on September 11, 2025. The program promotes translational research and encourages collaborations with experienced clinical trialists serving as designated mentors. Successful proposals must demonstrate access to diverse patient populations, an understanding of statistical methods, and a viable recruitment strategy. The initiative underscores the Defense Health Program's mission to advance research that enhances health outcomes for Service Members, Veterans, and all women impacted by ovarian cancer. By integrating research with career development, the OCCTA aims to equip ECIs with the skills needed for independent careers in cancer research.
    OCRP_FY25.pdf
    The Fiscal Year 2025 (FY25) Department of Defense Ovarian Cancer Research Program (OCRP) offers the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award aimed at supporting early-career investigators. Applicants must meet specific eligibility criteria, including being within 12 years of completing their last postdoctoral research position or clinical fellowship by the submission deadline of September 11, 2025. Furthermore, candidates are required to commit at least 25% of their time to the award activities during the first two years. The application includes a certification section for both the Principal Investigator (PI) and an official from the PI’s organization to affirm the eligibility requirements and commitment to the award. This funding opportunity emphasizes supporting emerging researchers in ovarian cancer clinical trials and enhancing the research landscape in this critical area of health.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Paul Calabresi Career Development Award for Clinical Oncology (K12), aimed at supporting institutional research career development programs for clinical scientists in cancer research. This initiative emphasizes training for clinical scientists who aspire to lead independent clinical trials or contribute to existing trials, thereby enhancing the field of clinical cancer research. The NOFO is anticipated to be released in November 2024, with the first application deadline set for February 2025, and the estimated award date is January 5, 2026. Interested applicants are encouraged to begin developing collaborations and applications in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), is offering a funding opportunity titled "Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis" under the R01 Research Project Grant program. This initiative aims to support research projects that implement early phase clinical trials (Phases 0, I, and II) focused on cancer-targeted diagnostic and therapeutic interventions, aligning with the NCI's mission to advance cancer research. Eligible applicants include a diverse range of organizations such as colleges, nonprofits, and governmental entities, with a maximum project budget of $499,999 in direct costs per year and an award period not exceeding five years. Interested parties should note that applications are due by January 7, 2027, and can seek further information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-081.html.
    Forecast to Publish a Notice of Funding Opportunity for Paul Calabresi Career Development Award in Clinical Oncology (K12 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Paul Calabresi Career Development Award in Clinical Oncology (K12), aimed at enhancing the training of clinical scientists in cancer research. This grant program is designed to support institutional research career development programs that will increase the number of clinician-scientists engaged in clinical and translational cancer research, fostering their career development through tailored mentorship and individualized plans. The program will fund a total of 15 awards, with support for a minimum of two years and a maximum of three years for each scholar, covering salary, research, and administrative costs. Interested applicants can reach out to Mark Damico, Ph.D., at damicomw@nih.gov or call 240-276-5630 for further information, with the estimated synopsis posting date on December 1, 2025, and applications expected to close by February 18, 2026.
    The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12), aimed at supporting newly trained clinicians committed to independent research careers in community oncology and cancer prevention. This grant opportunity encourages the development of community-based clinical trials and ancillary studies, with a strong emphasis on addressing health disparities and improving access to cancer clinical trials for underserved populations. Eligible applicants include a diverse range of organizations, particularly those serving underrepresented groups, with funding available for up to five years to support program planning and mentorship. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for February 18, 2027.
    Novel approaches to support therapeutic development in ultra-rare cancers
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Academic Career Excellence (ACE) Award (K32 - Independent Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Academic Career Excellence (ACE) Award (K32), which requires an independent clinical trial. This grant aims to support late-stage graduate students and early-stage postdoctoral scholars in cancer research, specifically targeting those transitioning to postdoctoral positions or within the first two years of their postdoctoral training. The ACE Award is crucial for enhancing the scientific research and career development of candidates, as it provides essential training support and encourages the development of a robust research plan with a designated mentor. Interested applicants should note that the first due date for submissions is anticipated to be June 12, 2025, with an estimated award date of March 2, 2026. For further details, applicants can refer to the NIH website or contact the agency directly.
    Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the "Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)," aimed at enhancing the training of a workforce to meet the nation’s biomedical and clinical research needs, particularly in cancer research. This program seeks applications that propose innovative educational activities, specifically hands-on cancer research experiences lasting 8 to 15 weeks, complemented by additional educational initiatives. With a funding ceiling of $300,000 per year for a project period of up to five years, the program encourages participation from underrepresented groups and aims to provide unique educational opportunities not covered by existing programs. Interested applicants can find more information and guidelines at the NIH website, with the application deadline set for January 25, 2026.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.